Guggenheim analyst Michael Schmidt maintains a Buy rating on Adaptimmune (ADAP) after the company announced that it has agreed on the terms for transferring GSK‘s (GSK) autologous TCR T cell therapies targeting PRAME and NY-ESO back to the company in Q3. The return of the funded assets complements Adaptimmune’s TCR pipeline following the recent acquisition of TCR2 (TCRR) and adds "free" optionality, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADAP:
- Adaptimmune initiated with a Buy at Bryan Garnier
- TCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
- TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue